Editorial European Journal of Nuclear Medicine and Molecular Imaging by Ambros J. Beer & Ingrid Dijkgraaf
EDITORIAL COMMENTARY
Editorial European Journal of Nuclear Medicine
and Molecular Imaging
Ambros J. Beer1 & Ingrid Dijkgraaf2
Published online: 7 November 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
In this issue of The European Journal of NuclearMedicine and
Molecular Imaging, Xiaohui Luan et al. at Shandong Cancer
Hospital report the role of 18F-alfatide positron emission
tomography/computed tomography (PET/CT) for assessment
of integrin αvβ3 expression in predicting the short-term out-
come of concurrent chemoradiotherapy (CCRT) in patients
with advanced non-small cell lung cancer (NSCLC). There
is a need for an effective predicting tool to select patients with
advanced NSCLC who may benefit from CCRT, which rep-
resents the standard of therapy protocol, because one-third of
these patients experience local failure. Molecular imaging of
specific biological targets known to play a role in tumour
biology and aggressiveness lends itself for this purpose.
Especially, the integrin αvβ3 has gained interest in this re-
spect as it is known to be overexpressed on activated endo-
thelial cells in angiogenesis and also on many tumour cells
and plays an important role in cell–cell and cell–matrix inter-
actions in general. In the past two decades, the potential of
using radio-labelled arginine-glycine-aspartic acid (RGD)-
containing peptides to serve as imaging agents for noninva-
sive evaluation of integrin expression has been profoundly
investigated by several research groups. For the development
of a clinically suitable αvβ3 integrin-binding radiopharma-
in vivo stability, high receptor affinity, favorable pharmacoki-
netics and pharmacodynamics, and low toxicity and immuno-
genicity, the radiolabelling procedure should be rapid and
without the necessity of laborious purification steps.
The first clinically applied RGD-based PET radiotracer
which meets most of the above-mentioned conditions for im-
aging αvβ3 expression in tumours was [18F]Galacto-RGD.
This radiotracer cleared rapidly from the blood pool, showed
predominantly renal excretion, and could successfully image
integrin expression in human tumours with good tumour-to-
background ratios [1–3]. It appeared that molecular imaging
of αvβ3 expression, with [18F]Galacto-RGD in humans cor-
related with αvβ3 expression, as determined by immunohis-
tochemistry [4].
Another 18F-labelled RGD peptide that has clinically been
tested is 18F-AH111585 [5]. This PET tracer was demonstrat-
ed to be safe and well tolerated, with no adverse events in the
patients studied. All primary and metastatic lesions that were
identified on CT within the PET field of view were detected
with 18F-AH111585 PET.
However, the PET radiotracers described above are
peptides based on monomeric cyclic RGD and compar-
ison studies of integrin-binding affinities of multimeric
(i.e. dimeric, tetrameric, and octameric) RGD peptides
with their monomeric analogs revealed significantly in-
creasing affinities in the series monomer < dimer <
tetramer < octamer [6–10] . In general, both tumour
uptake and tumour-to-organ ratios increased for
multimeric RGD peptides, resulting in improved tu-
mour imaging. However, it is important to note that
RGD-multimerisation has its limitations as a higher de-
gree of oligomerisation not only led to a higher tumour
uptake of the tracer, but also caused a higher tracer
uptake in non-target tissues, especially the kidneys.
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ceutical, and radiopharmaceuticals in general, several chal-
lenges have to be taken into account. Aside from sublime
This will decrease detection sensitivity in the proximity
of the kidneys and could cause radiation nephrotoxicity
in therapeutic applications which necessitates use of
other tracer optimisation strategies.
Besides the fact that [18F]Galacto-RGD and 18F-
AH111585 are monomeric RGD-based agents, both tracers
are radiofluorinated via prosthetic groups which involves mul-
tistep time-consuming and low-yield synthetic procedures,
limiting their widespread use as routine tracers in the clinic.
The recent development of [18F]-fluoride–aluminum com-
plexes to radiolabel peptides via chelation chemistry simpli-
fied and shortened radiofluorination of peptides and even al-
lows kit formulation, facilitating clinical translation [11].
The newly developed 18F-AlF-NOTA-PRGD2, denoted as
18F-alfatide, combines both utilities: facile one-pot Al18F-
radiofluorination and multivalency by having two RGD moi-
eties [12, 13]. After optimisation of radiolabelling conditions
(e.g. temperature and pH), the whole radiosynthesis and sub-
sequent purification can be performed within 20 min with a
decay-corrected yield of 42.1 ± 2.0 % and radiochemical pu-
rity of more than 95 %. In the first clinical studies, 18F-
alfatide-PET allowed specific imaging of αvβ3 expression
in lung cancers with good contrast [14]. Additionally, it ap-
peared that 18F-alfatide-PET/CT parameters can predict tumor
sensitivity to CCRT in patients with glioma [15]. From the
18F-alfatide-PET/CT study, described in this European
Journal of Nuclear Medicine and Molecular Imaging’s issue,
it appeared that the maximum standardized uptake value
(SUVmax) , SUVpeak, T/NTlung, T/NTblood, and T/NTmuscle
were higher in non-responders than responders and that 18F-
alfatide PET/CT might be useful in predicting the short-term
outcome of CCRT in patients with advanced NSCLC.
While this is an interesting preliminary study on the poten-
tial predictive value of 18F-alfatide PET/CT in patients with
NSCLC before undergoing CRRT, final conclusions cannot
yet be drawn on the ultimate clinical usefulness of this ap-
proach in the presented setting. Now, studies with larger pa-
tient collectives are warranted to corroborate the presented
results. Moreover, a comparison to other functional and mo-
lecular imaging techniques for evaluation of tumour biology,
patient prognosis and response to therapy should be per-
formed as well, like FDG PET/CT or perfusion/diffusion im-
aging with magnetic resonance imging (MRI).
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M,
et al. Noninvasive visualization of the activated alphavbeta3
integrin in cancer patients by positron emission tomography and
[18F]Galacto-RGD. PLoS Med. 2005;2:e70.
2. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME,
Wester HJ, et al. Biodistribution and pharmacokinetics of the
alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J
Nucl Med. 2005;46:1333–13341.
3. Beer AJ, Haubner R,Wolf I, Goebel M, Luderschmidt S, Niemeyer
M, et al. PET-based human dosimetry of 18F-galacto-RGD, a new
radiotracer for imaging alpha v beta3 expression. J Nucl Med.
2006;47:763–9.
4. Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S,
Grosu AL, et al. Positron emission tomography using
[18F]Galac to-RGD ident i f ies the level of in tegr in
alpha(v)beta3 expression in man. Clin Cancer Res.
2006;12:3942–9.
5. Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M,
Spinks TJ, et al. Phase I trial of the positron-emitting Arg-Gly-
Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer
patients. J Nucl Med. 2008;49:879–86.
6. Janssen MLH, Oyen WJG, Massuger LFAG, Frielink C, Dijkgraaf
I, Edwards DS, et al. Comparison of a monomeric and dimeric
radiolabeled RGD-peptide for tumor imaging. Cancer Biother
Radiopharm. 2002;17:641–6.
7. Dijkgraaf I, Kruijtzer JA, Liu S, Soede AC, OyenWJ, Corstens FH,
et al. Improved targeting of the alpha(v)beta (3) integrin by
multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging.
2007;34:267–73.
8. Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, et al. (64)Cu-labeled
tetrameric and octameric RGD peptides for small-animal PET of
tumor alpha(v)beta(3) integrin expression. J Nucl Med. 2007;48:
1162–71.
9. Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M,
Henriksen G, et al. Two-step methodology for high-yield routine
radiohalogenation of peptides: 18F-labeled RGD and octreotide an-
alogs. J Nucl Med. 2004;45:892–902.
10. Poethko T, Schottelius M, Thumshirn G, Herz M, Haubner R,
Henr iksen G, e t a l . Chemose lec t ive pre -con juga te
radiohalogenation of unprotected mono- and multimeric peptides
via oxime formation. Radiochim Acta. 2004;92:317–27.
11. McBride WJ, Sharkey RM, Karacay H, D’Souza CA, Rossi EA,
Laverman P, et al. A novel method of 18F radiolabeling for PET. J
Nucl Med. 2009;50:991–8.
12. Lang L, Li W, Guo N, Ma Y, Zhu L, Kiesewetter DO, et al.
Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2,
and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors
in mice. Bioconjug Chem. 2011;22:2415–22.
13. Guo N, Lang L, Li W, Kiesewetter DO, Gao H, Niu G, et al.
Quantitative analysis and comparison study of [18F]AlF-NOTA-
PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 using a ref-
erence tissue model. PLoS ONE. 2012;7:e37506.
14. WanW, Guo N, Pan D, Yu C,Weng Y, Luo S, et al. First experience
of 18F-alfatide in lung cancer patients using a new lyophilized kit
for rapid radiofluorination. J Nucl Med. 2013;54:691–8.
15. Zhang H, Liu N, Gao S, Hu X, Zhao W, Tao R, et al. Can an 18F-
ALF-NOTA-PRGD2 PET/CT scan predict treatment sensitivity to
concurrent chemoradiotherapy in patients with newly diagnosed
glioblastoma? J Nucl Med. 2016;57:524–9.
Eur J Nucl Med Mol Imaging (2017) 44:284–285 285
